Evidence map›Paper›PMID 42668879›Full record

ArticleInternational journal of nanomedicine2026

Combined Enzyme-Responsive Nano-Peptide Drug with Photothermal Function for Effective Anti-Hepatocellular Carcinoma in Mice Model.

Yuqing Zhu, Kun Chen, Shi Feng, Junchen Li, Ruyue Yuan, Mengping Gao, Xiujuan Fu, Siwei Chen, Yaling Li, Dan Zhang

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuqing Zhu *Department of Traditional Chinese Medicine Processing and Preparation, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.
Kun Chen *Department of Technology and Social Services, Dazhou Vocational College of Chinese Medicine, Dazhou, Sichuan, 635000, People's Republic of China.
Shi FengDepartment of Traditional Chinese Medicine Processing and Preparation, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.
Junchen LiSchool of Clinical Medicine, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.
Ruyue YuanDepartment of Traditional Chinese Medicine Processing and Preparation, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.
Mengping GaoDepartment of Traditional Chinese Medicine Processing and Preparation, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.
Xiujuan FuDepartment of Traditional Chinese Medicine Processing and Preparation, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.
Siwei ChenDepartment of Traditional Chinese Medicine Processing and Preparation, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.
Yaling LiDepartment of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.
Dan ZhangDepartment of Traditional Chinese Medicine Processing and Preparation, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.ORCID 0000-0001-9651-8194

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The efficacy of photothermal therapy (PTT) for hepatocellular carcinoma (HCC) is severely constrained by tumor heat resistance, which is driven by heat shock protein (HSP) upregulation, alongside the limited tissue penetration of near-infrared (NIR) laser. Methods: An enzyme-responsive "peptide-drug" sequence (PD) was combined with gold nanorods (GNR) to construct a tumor-targeting microgel system (GNR/PD-M). The formulation was comprehensively evaluated in HepG2 cells and BALB/c nude mice bearing subcutaneous HCC xenografts, with key assessments including MMP-2-responsive drug release, in vitro cytotoxicity, mitochondrial and tumor targeting specificity, in vivo anti-tumor efficacy, and biosafety profiles. Results: In both cellular and animal models, the GNR/PD-M + laser irradiation group exhibited the strongest tumor cell inhibition. Mechanistically, this treatment significantly downregulated HSP90 expression and disrupted mitochondrial function, thereby overcoming tumor heat resistance and reducing tumor cell viability. Consistently, the in vivo anti-tumor effect of GNR/PD-M + laser was markedly superior to that of the control groups. Conclusion: The GNR/PD-M system synergistically enhances PTT efficacy against HCC by mitochondrial targeting and heat resistance reversal, representing a promising strategy for intelligent and targeted drug delivery.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularLiver NeoplasmsPeptidesPhotothermal TherapyAnimalsCell SurvivalGoldHep G2 CellsHumansMiceMice, Inbred BALB CMice, NudeNanotubesXenograft Model Antitumor AssaysAntineoplastic AgentsGoldPeptidesgold nanorodshepatocellular carcinomamitochondrial targetingpeptide-drug conjugatephotothermal therapy

Identifiers

PMID42668879
PMCPMC13525813

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.